Elaine Burridge

Photo

LyondellBasell Wins Vietnam PP Project

LyondellBasell has been awarded a contract by Hyosung Vina Chemicals to supply its Spheripol PP technology for a new plant to be built in the Cai Mep industrial zone in Vung Tau province, Vietnam.

Photo

Lucite and Agilyx Partner on PMMA

Acrylic-based products manufacturer Lucite International, part of the Mitsubishi Chemical Group, is working with Agilyx to define the most suitable chemical recycling infrastructure for polymethyl methacrylate (PMMA).

Photo

Sartorius Closes Danaher Acquisition

German pharma and laboratory equipment supplier Sartorius completed its $825 million purchase of certain life science businesses of Danaher Corps at the end of April.

Photo

Axens Wins China Aromatics Project

French technology provider Axens has won a contract from China’s CNOOC Huizhou Petrochemical Co. Ltd. (CHPCL) for an aromatics expansion project in Daya Bay.

Photo

Huntsman in Vietnam Textiles Collaboration

Huntsman Textile Effects, a producer of dyes, chemicals and digital inks for the textile and related industries, has announced a strategic partnership with Phong Phu International (PPJ), a Vietnamese garment manufacturer and exporter.

Photo

IMCD Opens Dubai Office

IMCD, the Netherlands-based specialty chemicals and food ingredients distributor, has opened an office in Dubai, strengthening its presence in the Middle East.

Photo

Linde and Hyosung in Hydrogen JV

Linde has signed an agreement with South Korean conglomerate Hyosung to build what they said will be the world’s single largest liquid hydrogen manufacturing plant, at Hyosung’s Ulsan site. 

Photo

Seqens Invests in Second IPA Plant

Seqens, a French provider of pharmaceutical synthesis and specialty ingredients, is planning to invest an undisclosed sum in a second isopropanol (IPA) production plant at Roussillon.

1962 more articles

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.